Blockchain Registration Transaction Record

NurExone Biologic to Present at Moody Capital Solutions 2026 Conference

NurExone Biologic to showcase exosome-based therapies at Moody Capital Solutions 2026 conference in NYC, Sept 9-10. CEO to present, highlighting pipeline and U.S. plans.

NurExone's participation in the Moody Capital Solutions conference is a critical step in its journey to commercialize innovative exosome-based therapies for central nervous system injuries. For investors and the biotech community, this news signals potential advancements in treatments for spinal cord and optic nerve damage, which currently have limited options. The company's progress could lead to groundbreaking therapies that improve patients' lives, making it essential for stakeholders to monitor its development. Additionally, NurExone's efforts to establish manufacturing and commercialization in the U.S. could create economic opportunities and position the company as a leader in regenerative medicine.